US 12,404,322 B2
Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease
Michal Novák, Bratislava (SK); Eva Kontseková, Senec (SK); Branislav Kovácečh, Bratislava (SK); and Norbert Zilka, Senec (SK)
Assigned to Axon Neuroscience SE, Larnaca (CY)
Filed by AXON NEUROSCIENCE SE, Cyprus (CY)
Filed on Jul. 27, 2021, as Appl. No. 17/443,779.
Application 15/801,341 is a division of application No. 15/599,685, filed on May 19, 2017, granted, now 9,845,352, issued on Dec. 19, 2017.
Application 15/342,629 is a division of application No. 14/345,561, granted, now 9,518,101, issued on Dec. 13, 2016, previously published as PCT/IB2012/002246, filed on Sep. 14, 2012.
Application 17/443,779 is a continuation of application No. 15/801,341, filed on Nov. 2, 2017, granted, now 11,098,106.
Application 15/599,685 is a continuation of application No. 15/342,629, filed on Nov. 3, 2016, granted, now 9,828,421, issued on Nov. 28, 2017.
Claims priority of provisional application 61/653,115, filed on May 30, 2012.
Claims priority of provisional application 61/536,339, filed on Sep. 19, 2011.
Prior Publication US 2022/0010004 A1, Jan. 13, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); A61K 49/00 (2006.01); C07K 14/47 (2006.01); C07K 16/18 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 38/1709 (2013.01); A61K 39/0007 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/6843 (2017.08); A61K 47/6849 (2017.08); A61K 49/0004 (2013.01); C07K 14/4711 (2013.01); G01N 33/53 (2013.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/6081 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/70 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/52 (2013.01)] 23 Claims
OG exemplary drawing
 
1. An anti-tau antibody or antigen-binding fragment thereof that binds to one or more tau epitopes, wherein the antibody or antigen-binding fragment comprises:
a) a light chain variable region comprising a complementarity determining region (CDR) 1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 254; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 122;
b) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 119; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 265, and a CDR3 comprising SEQ ID NO: 122;
c) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 119; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 267;
d) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 119; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 269;
e) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 248, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 119; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 122;
f) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 253, and a CDR3 comprising SEQ ID NO: 119; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 122;
g) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 255; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 122;
h) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 257; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 122;
i) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 258; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 122;
l) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 259; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 122;
k) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 260; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 122;
l) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 119; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 261, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 122;
m) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 119; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 262, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 122;
n) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 119; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 264, and a CDR3 comprising SEQ ID NO: 122; or
o) a light chain variable region comprising a CDR1 comprising SEQ ID NO: 117, a CDR2 comprising SEQ ID NO: 118, and a CDR3 comprising SEQ ID NO: 119; and a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 120, a CDR2 comprising SEQ ID NO: 121, and a CDR3 comprising SEQ ID NO: 266.